Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Retained Earnings (2016 - 2025)

Assembly Biosciences has reported Retained Earnings over the past 11 years, most recently at -$41000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at -$41000.0 for Q4 2025, up 80.57% from a year ago — trailing twelve months through Dec 2025 was -$41000.0 (up 80.57% YoY), and the annual figure for FY2025 was -$41000.0, up 80.57%.
  • Retained Earnings for Q4 2025 was -$41000.0 at Assembly Biosciences, up from -$854.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for ASMB hit a ceiling of -$41000.0 in Q4 2025 and a floor of -$854.1 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$276.7 million (2021), compared with a mean of -$366.4 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 99.98% in 2024 and later tumbled 547423.72% in 2025.
  • Assembly Biosciences' Retained Earnings stood at -$631.4 million in 2021, then soared by 99.87% to -$803000.0 in 2022, then tumbled by 97751.56% to -$785.7 million in 2023, then skyrocketed by 99.97% to -$211000.0 in 2024, then skyrocketed by 80.57% to -$41000.0 in 2025.
  • The last three reported values for Retained Earnings were -$41000.0 (Q4 2025), -$854.1 million (Q3 2025), and -$844.9 million (Q2 2025) per Business Quant data.